EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

10. How can clinics source branded GLP-1 medicines, and is the cash price a wholesale price?

Dose Diligence research deskSection 01 · Page 10 of 34Last updated 17 Nov 2026

Source clinic inventory through an eligible purchasing relationship; source patient prescriptions through an appropriate dispensing route. A published patient cash offer is not evidence of a clinic’s acquisition price or resale rights. FDA advises purchasing prescription medicines only from properly licensed and authorized wholesale distributors, while manufacturer programmes describe patient-specific offers. (fda.gov)

For a wholesale request, specify:

  • Clinic legal entity, licences and shipping locations.
  • Exact brand, National Drug Code where applicable, strength and presentation.
  • Intended administration or dispensing model.
  • Forecast quantities by presentation—not simply total patients.
  • Payment terms, minimums, allocation rules and returns.
  • Traceability and cold-chain responsibilities.

McKesson publishes account-request and pharmaceutical-ordering resources, but those resources do not establish GLP-1 availability for a particular clinic. (mms.mckesson.com)

No public wholesale benchmark is offered here. Obtain account-specific quotations before claiming a difference between clinic acquisition cost and patient self-pay expenditure.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-supply-chain-integrity/check-licensure-wholesale-drug-distributors-and-third-party-logistics-providers?utm_source=openai
  2. mms.mckesson.com · Source 2 ↗https://mms.mckesson.com/content/request-an-account/?utm_source=openai
Section sources →